Distalmotion lands up to $70M debt facility for US surgical robot push
What's the deal? Distalmotion, a Lausanne-based surgical robotics company, has secured a senior secured term loan facility of up to $70 million from healthcare investor Perceptive Advisors. The capital will fund its expansion into the US ambulatory surgery center (ASC) market and further development of its DEXTER Robotic Surgery System.
Why debt? The financing follows a $150 million Series G round in November 2025 and a strategic investment from Johnson & Johnson Innovation in January 2026. This time the company opted for debt rather than another equity raise to fund its capital-intensive US rollout.
What's the endgame? Distalmotion is betting on the shift of surgery from hospitals to outpatient settings. DEXTER is designed with a small, mobile footprint and single-use instruments to fit into ASCs without the infrastructure that traditional robotic platforms require.
Why now? The loan builds on growing US commercial momentum. In August, the FDA cleared DEXTER for ventral hernia repairs, a high-volume outpatient procedure, adding to existing clearances for cholecystectomy, inguinal hernia repair, and hysterectomy.
Rare company: The facility is notable by size. Among debt rounds raised by Swiss deep tech companies over the trailing 48 months, it ranks in the top 1% of a 60-deal sample.
"This financing gives us additional capital to accelerate our US growth strategy, strengthen our commercial presence, and continue to optimize DEXTER for ASC patients, surgeons, and administrators," said Greg Roche, chief executive officer of Distalmotion.
What could go wrong? The announcement does not disclose how much will be drawn or the facility's pricing and covenants. Competition is also intensifying: Intuitive is placing refurbished da Vinci systems, while CMR Surgical and Moon Surgical are pursuing the same outpatient market.
The signal: Distalmotion's choice of debt over equity points to a maturing growth story — one where lenders, not just venture backers, are willing to bankroll the move of robotic surgery into cost-conscious outpatient settings.
Read more: markets.financialcontent.com
Image credit: NavyMedicine
